Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) saw unusually large options trading activity on Thursday. Traders purchased 1,116 call options on the company. This is an increase of 1,792% compared to the average daily volume of 59 call options.

Several research analysts have recently issued reports on TTPH shares. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 28th. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, December 5th. BMO Capital Markets increased their price objective on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. Finally, ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $15.15.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up $0.14 during mid-day trading on Monday, reaching $6.42. 315,005 shares of the company’s stock were exchanged, compared to its average volume of 500,242. The stock has a market capitalization of $330.08, a PE ratio of -2.24 and a beta of 2.51. Tetraphase Pharmaceuticals has a twelve month low of $3.57 and a twelve month high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.63). The firm had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The company’s revenue for the quarter was up 355.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.58) earnings per share. analysts predict that Tetraphase Pharmaceuticals will post -2.88 EPS for the current year.

In related news, insider Jacques Dumas sold 8,750 shares of the business’s stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the transaction, the insider now owns 8,750 shares in the company, valued at $52,762.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director L Patrick Gage purchased 3,880 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Wednesday, November 29th. The shares were bought at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the transaction, the director now directly owns 38,880 shares of the company’s stock, valued at $250,776. The disclosure for this purchase can be found here. Insiders own 5.50% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Canada Pension Plan Investment Board grew its stake in Tetraphase Pharmaceuticals by 54.4% during the third quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock valued at $17,470,000 after acquiring an additional 900,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Tetraphase Pharmaceuticals by 32.7% during the third quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock valued at $9,998,000 after purchasing an additional 360,552 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Tetraphase Pharmaceuticals during the third quarter valued at $7,915,000. Northern Trust Corp lifted its position in Tetraphase Pharmaceuticals by 4.8% during the second quarter. Northern Trust Corp now owns 886,765 shares of the biopharmaceutical company’s stock valued at $6,323,000 after purchasing an additional 40,668 shares during the last quarter. Finally, Numeric Investors LLC lifted its position in Tetraphase Pharmaceuticals by 1,363.3% during the second quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock valued at $5,379,000 after purchasing an additional 702,812 shares during the last quarter. 58.57% of the stock is owned by institutional investors.

WARNING: This story was reported by Marea Informative and is owned by of Marea Informative. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.mareainformativa.com/2018/01/29/investors-purchase-high-volume-of-call-options-on-tetraphase-pharmaceuticals-ttph-updated-updated-updated.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.